HENDERSON, Nev., Oct. 27, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces that it has executed a non-binding Letter of Intent (“LOI”) with Missionpharma A/S, a Danish global leader in the sale and distribution of healthcare products and innovative solutions, impacting the lives of over 100 million patients annually, regarding the potential development and launch of Volition’s prototype Lateral Flow Technology (“LFT”) for NETosis.

Dr. Gaetan Michel, Chief Operating Officer, Volition, commented:

“We recently announced a major technical milestone: results utilizing our lateral flow prototype are highly correlated with results utilizing Volition’s established automated Nu.Q® NETs test in critically ill sepsis patients¹, thereby expanding beyond centralized laboratory testing. This finger prick sample test could be used worldwide, beyond solely high-income countries.

“The Nu.Q® NETs test quantifies circulating nucleosomes and Neutrophil Extracellular Traps (NETs) as early indicators of hyper-inflammation, and we believe its use will cover a broad range of diseases including sepsis and septic shock.

“By enabling decentralized testing, our total addressable market expands, and, with the help of Missionpharma, we hope to accelerate commercialization and market access, particularly in resource-constrained countries and humanitarian emergency settings.”

Agustin Travaini, Director, Strategic Partnerships, UN, Missionpharma, commented:

“At Missionpharma, we are proud to have strong partnerships with a broad institutional base, including United Nations (“UN”) agencies specialized in global health and humanitarian response.

“We aim to explore opportunities to closely work with Volition in the introduction, development, and scale-up of its LFT test for NETosis, potentially assisting with low-cost manufacturing, clinical studies, and distribution.

“We see a very strong interest from our partners and customers in Volition’s innovative diagnostic solutions, particularly in low- and middle-income countries (“LMICs”) and humanitarian emergency settings, and are excited to collaborate with the aim of saving millions of children’s lives annually.”

Dr Andrew Retter, Medical Consultant, Volition, said:

“The proprietary Nu.Q® technology, including Volition’s finger-prick lateral flow prototype, has broad clinical utility.

“Following on from discussions with key global health institutions, it is clear that Volition’s clinical intended use should initially focus on one well defined use: developing and validating a tool for triaging and prognostication for neonatal sepsis (sepsis in newborns and young infants).

“An estimated 2.3 million newborns die each year². Sepsis is a major contributor in settings such as LMICs, especially in Africa, which bears the greatest mortality burden. Severe infections are among the major causes of newborn deaths. Studies have shown that 84% of these deaths could be spared if an early diagnosis and patient management tools were available³.

“The Nu.Q® NETs LFT prototype test is a potential gamechanger. We are delighted that Volition and Missionpharma have now established a basis for collaboration with initial focus on evaluating the lateral flow prototype with a well-defined and impactful first clinical utility, sepsis in newborns and young infants.

“We look forward to continuing our work together with Missionpharma.”

For partnership, licensing, or media inquiries, contact our alliance team directly at mediarelations@volition.com.

1. Data on File, Volition
2. The United Nations Inter-agency Group for Child Mortality Estimation. Levels and trends in child mortality: Report 2025 (accessed Sept 2026)
3. Global report on the epidemiology and burden of sepsis: current evidence, identifying gaps and future directions. Geneva: World Health Organization; 2020 Report (accessed Sept 2026)

About Missionpharma

Missionpharma is a global leader in the sale and distribution of healthcare products and innovative solutions, supplying UN agencies, international and local non-governmental development organizations, and public and private sector institutions, including the WHO and Ministries of Health across LMICs.

Since 1975 Missionpharma has contributed to improving global health by supplying quality medicines, medical devices, and health kits to people all over the world, every year improving the lives of more than 100 million people.

Since 2012, Missionpharma has been a proud member of CFAO Healthcare, the healthcare division of CFAO Group, owned by Toyota Tsusho Corporation. 

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

The contents found at Volition’s website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries: Ellen Amonoo, Volition, mediarelations@volition.com

Safe Harbor Statement

Statements in this press release or associated video or link may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition’s expectations related to revenue opportunities and growth, the effectiveness and availability of Volition’s blood-based diagnostic, prognostic and disease monitoring tests, Volition’s ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition’s expectations regarding future publications, Volition’s success in securing licensing and/or distribution agreements with third parties for its products, and Volition’s expectations regarding the terms of such agreements. Volition’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition’s development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition’s failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition’s intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nu.Q®, rNuq™, Nucleosomics™, Capture-PCR™ and Capture-Seq™ and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to “$” refer to the legal currency of the United States of America.

View original content:https://www.prnewswire.com/news-releases/volitionrx-signs-loi-with-missionpharma-to-explore-the-development-and-launch-of-volitions-lateral-flow-technology-for-netosis-worldwide-302920590.html

SOURCE VolitionRx Limited